Sangamo puts substantially all assets up for sale in bankruptcy, lines up Lilly and Astellas as buyers
Sangamo puts substantially all assets up for sale in bankruptcy, lines up Lilly and Astellas as buyers
Sangamo Therapeutics has filed for Chapter 11 bankruptcy and will put substantially all of its assets up for sale through a court-supervised process. The company has lined up Eli Lilly and Astellas Pharma as "stalking horse" bidders for key assets, with Lilly targeting Sangamo's capsid delivery, zinc finger, and MINT genome‑editing platforms plus the prion disease program ST‑506, and Astellas targeting the Fabry disease gene therapy candidate isaralgagene civaparvovec (ST‑920). Sources: Sangamo to put 'substantially all' assets for sale in bankruptcy, lines ... Sangamo申请破产 基因治疗平台待售 礼来与安斯泰来正密切关注 Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle Chapter 11, asset sales and layoffs at Sangamo Therapeutics (SGMO) Form 10-Q for Sangamo Therapeutics INC filed 11/06/2025 [PDF] Form 424B5 for Sangamo Therapeutics INC filed 02/04/2026 Sangamo dépose le bilan et signe des accords de cession d’actifs avec Lilly Par Invest...
- Get link
- X
- Other Apps